Literature DB >> 22819384

On typing amyloidosis using immunohistochemistry. Detailled illustrations, review and a note on mass spectrometry.

Reinhold P Linke1.   

Abstract

Every amyloid disease needs to be assessed for chemical composition of its amyloid because amyloid is pathogenetically diverse and each of the chemical amyloid types requires a different therapy. Basically four different approaches are being applied for typing of amyloid using immunohistochemistry, immunochemistry, mass spectrometry and chemistry. It is shown here how an easy immunohistochemical procedure has been developed over the years that can be used to classify specifically amyloid proteins for clinico-pathologic routine use. A larger number of tissues with chemically or immunochemically typed amyloids served as prototypes for developing a set of validated amyloid antibodies. These were examined for their performance to classify a larger number of tissues of patients submitted to us and other institutions allowing independent evaluation. The data reveal that out of 663 patients, including 15 different amyloid types, all 119 prototype Amyloids (100%) have been classified correctly and 97.9% of consecutive 581 unknown amyloid tissues submitted for typing to our laboratory of whom 37 became later prototypes. Twelve samples (2.1%) could not be classified. By using appropriate amyloid antibodies in a comparative manner, this procedure is accurate. It identifies the respective amyloid type and excludes simultaneously other amyloids. Its improved performance leads to an accurate amyloid diagnosis in most cases and provides a diagnostic marker which is independend of any other information for therapeutic considerations. These results can be obtained within a day in institutes competent in performing immunohistochemistry. This is the first report on immunhistochemical typing of amyloid providing detailed illustrations of the original results for training purposes. When the immunohistochemical method presented here was compared with mass spectrometry, a more recent method for amyloid typing, the advantages and failures of both methods became apparent in an international blinded comparison.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22819384     DOI: 10.1016/j.proghi.2012.03.001

Source DB:  PubMed          Journal:  Prog Histochem Cytochem        ISSN: 0079-6336


  15 in total

Review 1.  Leukocyte Cell-Derived Chemotaxin 2-Associated Amyloidosis: A Recently Recognized Disease with Distinct Clinicopathologic Characteristics.

Authors:  Samih H Nasr; Ahmet Dogan; Christopher P Larsen
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-14       Impact factor: 8.237

2.  Discordant results between biochemical and molecular transthyretin assays: lessons learned from a unique testing algorithm at the Mayo Clinic.

Authors:  Honey V Reddi; Brittany C Thomas; Kurt S Willkomm; Matthew J Ferber; Kandelaria M Rumilla; Kimiyo M Raymond; John F O'Brien; W Edward Highsmith
Journal:  J Genet       Date:  2013-12       Impact factor: 1.166

Review 3.  Fibrinogen alpha amyloidosis: insights from proteomics.

Authors:  Jessica Chapman; Ahmet Dogan
Journal:  Expert Rev Proteomics       Date:  2019-08-28       Impact factor: 3.940

4.  Application of confocal laser scanning microscopy for the diagnosis of amyloidosis.

Authors:  Chiara Castellani; Marny Fedrigo; Anna Chiara Frigo; Mila Della Barbera; Gaetano Thiene; Marialuisa Valente; Fausto Adami; Annalisa Angelini
Journal:  Virchows Arch       Date:  2017-02-20       Impact factor: 4.064

Review 5.  Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.

Authors:  David L Narotsky; Adam Castano; Jonathan W Weinsaft; Sabahat Bokhari; Mathew S Maurer
Journal:  Can J Cardiol       Date:  2016-05-13       Impact factor: 5.223

6.  Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy.

Authors:  Maike F Dohrn; Christoph Röcken; Jan L De Bleecker; Jean-Jacques Martin; Matthias Vorgerd; Peter Y Van den Bergh; Andreas Ferbert; Katrin Hinderhofer; J Michael Schröder; Joachim Weis; Jörg B Schulz; Kristl G Claeys
Journal:  J Neurol       Date:  2013-10-08       Impact factor: 4.849

7.  Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.

Authors:  Selma F Mohammed; Sultan A Mirzoyev; William D Edwards; Ahmet Dogan; Donna R Grogan; Shannon M Dunlay; Veronique L Roger; Morie A Gertz; Angela Dispenzieri; Steven R Zeldenrust; Margaret M Redfield
Journal:  JACC Heart Fail       Date:  2014-04       Impact factor: 12.035

Review 8.  Systemic AA amyloidosis: epidemiology, diagnosis, and management.

Authors:  Diego Real de Asúa; Ramón Costa; Jose María Galván; María Teresa Filigheddu; Davinia Trujillo; Julen Cadiñanos
Journal:  Clin Epidemiol       Date:  2014-10-29       Impact factor: 4.790

Review 9.  Proteomics and mass spectrometry in the diagnosis of renal amyloidosis.

Authors:  Maria M Picken
Journal:  Clin Kidney J       Date:  2015-09-11

10.  MALDI Mass Spectrometry Imaging: A Novel Tool for the Identification and Classification of Amyloidosis.

Authors:  Martin Winter; Andreas Tholey; Arnt Kristen; Christoph Röcken
Journal:  Proteomics       Date:  2017-11       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.